Xofluza is cleared to treat acute uncomplicated flu in patients 12 years and older who have had flu symptoms for no more than 48 hours.
“This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years. With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical. This novel drug provides an important, additional treatment option,” Scott Gottlieb, MD, FDA commissioner said.
The single-dose treatment will be available across the U.S. in a couple of weeks, a Genentech spokesperson told CNBC. The treatment will cost $150, although patients with commercial insurance may be able to access the drug for $30.
While Xofluza can treat the flu, Dr. Gottlieb noted the drug is not a flu vaccine replacement. The CDC recommends Americans receive a flu vaccine by the end of October.
More articles on supply chain:
Medline secures 2 new distributor partnerships
Express Scripts to expand network offerings to mail order pharmacies: 5 things to know
Hospitals could save $25.4B annually in supply chain costs, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
